KZIA - What's Going With Australia-Based Cancer Firm Kazia Therapeutics On Wednesday? | Benzinga
Wednesday morning, Kazia Therapeutics Limited (NASDAQ:KZIA) announced the early conclusion based on safety and clinical response findings observed to date of an important two-part Phase 1 trial.
During market trading, Kazia Therapeutics shares are trading lower after initially spiking higher amid increased volatility in the stock.
Soon after the trial update, the stock reached as high as $0.73 during the premarket session.
Kazia Therapeutics stock is trading on a strong volume of 19.17 million compared to an average volume of 230.237K as per data from Benzinga Pro.
The investigator-initiated ...